Managing Kidney Impairment

Core Conclusion

Kidney impairment occurs in up to 50% of multiple myeloma patients, with 15% to 20% suffering severe renal injury (creatinine > 177 μmol/L); rapid bortezomib-based induction alongside 3,000 mL daily hydration restores renal function in over 60% to 70% of cases.

Detailed Points

• (1) Causes of Kidney Damage in Myeloma: Myeloma cells produce excessive amounts of abnormal proteins called monoclonal "free light chains." Normally, your kidneys filter waste from your blood, but these light chains overwhelm the kidney's delicate filtering system. They clump together to form "casts" that physically block the kidney tubules, causing severe inflammation and damage—a condition known as myeloma cast nephropathy. Other factors like dehydration, high blood calcium (hypercalcemia), and certain medications can further stress and damage your kidneys.
• (2) The Importance of Hydration and Avoiding Nephrotoxic Drugs: To help flush these toxic light chains out of your body, aggressive hydration is absolutely critical. Your care team will recommend a high fluid intake of at least 3 liters per day to maintain a healthy urine output of 100 to 150 cc per hour$^{,}$. Additionally, you must strictly avoid "nephrotoxic" (kidney-damaging) substances. This includes over-the-counter NSAID pain relievers (like ibuprofen or naproxen), intravenous (IV) contrast dyes used for CT scans, and certain antibiotics or blood pressure medications$^{,}$.
• (3) Dose Adjustments for Common Medications: Because your kidneys help clear certain medications from your body, your doctor will carefully adjust your drug dosages based on your specific kidney function (creatinine clearance) to keep you safe from toxic buildup. For example, Lenalidomide (Revlimid) requires strict dose reductions: if you have moderate kidney impairment, your dose is generally reduced to 10 mg daily$^{,}$. For severe impairment not requiring dialysis, you may take 15 mg every 48 hours, and if you are on dialysis, you will typically take just 5 mg once daily (administered after your dialysis session).
• (4) Bortezomib-Based Regimens as the Cornerstone of Recovery: Bortezomib (Velcade) is considered the "gold standard" and the absolute cornerstone of treatment for myeloma-related kidney disease$^{,}$. Because it is metabolized by the liver rather than the kidneys, it is highly safe and requires zero dose reductions, even if you are on dialysis$^{,}$. It works incredibly fast to kill myeloma cells, plunging the production of toxic light chains and giving your kidneys the breathing room they need to recover.
• (5) The Role of Plasmapheresis and High Cut-Off Hemodialysis: You might wonder if mechanically filtering the blood (using plasmapheresis or special dialysis filters) is a good way to remove light chains. While it sounds logical, clinical trials have shown that these mechanical approaches alone do not improve overall survival or help patients get off dialysis faster$^{,,}$. Therefore, they have a very limited role and guidelines clearly state that starting your actual systemic anti-myeloma therapy should never be delayed to perform these filtering procedures$^{,}$.
• (6) Reversibility of Kidney Damage: The most encouraging news is that myeloma-related kidney damage is potentially entirely reversible$^{,}$. Because it is treated as a medical emergency, rapid initiation of treatment (especially regimens containing Bortezomib and high-dose Dexamethasone) can quickly reverse the damage, and many patients who initially require dialysis eventually recover enough kidney function to stop dialysis completely$^{,}$. Prompt action is the key, as delayed intervention can allow the damage to become permanent.

The above content is sourced from the following references

• Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
• NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma